证券代码：688133 证券简称：泰坦科技 公告编号：2025-021 上海泰坦科技股份有限公司 第四届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况： 上海泰坦科技股份有限公司（以下简称"公司"）第四届监事会第十四次会 议通知已于 2025 年 4 月 25 日以书面方式送达全体监事，会议于 2025 年 4 月 29 日在上海市徐汇区石龙路 89 号会议室以现场结合通讯方式召开，本次会议由监 事会主席顾梁先生召集并主持，应到监事 3 人，实到监事 3 人。本次会议的召集 和召开符合《中华人民共和国公司法》和《上海泰坦科技股份有限公司章程》等 相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况： 与会监事就如下议案进行了审议，并表决通过以下事项： 1、审议通过《关于<公司 2025 年第一季度报告>的议案》 根据《公司法》、《证券法》等相关法律法规、《公司章程》等内部规章的 规定及《上海证券交易所科创板股票上市规则》，公司编制了 2025 年第一季度 报告。 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥603,969,457.66, a decrease of 9.07% compared to the same period last year[4]. - Net profit attributable to shareholders increased by 122.27% to ¥5,129,765.53, driven by improved operational quality and government subsidies[4][8]. - Basic and diluted earnings per share rose by 50% to ¥0.03 per share[4][8]. - The company reported a net profit margin of approximately 0.28% for Q1 2025, down from 0.07% in Q1 2024[19]. - The net profit for Q1 2025 was CNY 1,855,610.93, an increase of 68.7% compared to CNY 1,099,310.93 in Q1 2024[20]. - The total comprehensive income for Q1 2025 was CNY 1,767,308.38, compared to CNY 1,203,726.29 in Q1 2024, reflecting a growth of 47%[21]. - Operating profit for Q1 2025 was CNY 2,392,234.71, a decrease of 18.8% from CNY 2,946,193.53 in Q1 2024[20]. Expenses and Costs - Research and development expenses totaled ¥37,871,158.33, accounting for 6.27% of operating revenue, an increase of 0.39 percentage points year-on-year[5]. - Total operating costs for Q1 2025 were RMB 601,897,479.15, down 9.05% from RMB 661,767,508.11 in Q1 2024[19]. - Operating costs included RMB 463,552,791.02 in cost of goods sold for Q1 2025, a decrease of 12.00% from RMB 526,100,925.06 in Q1 2024[19]. - The company incurred financial expenses of CNY 9,577,527.23 in Q1 2025, an increase of 35.5% from CNY 7,069,593.39 in Q1 2024[20]. - The company reported a decrease in sales expenses to CNY 45,226,581.01 in Q1 2025, down 15.5% from CNY 53,433,412.88 in Q1 2024[20]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,851,268,756.45, reflecting a slight increase of 0.05% from the end of the previous year[5]. - Current assets totaled RMB 3,084,338,957.65 as of March 31, 2025, a slight decrease from RMB 3,138,932,782.27 at the end of 2024[15]. - Non-current assets amounted to RMB 1,766,929,798.80 as of March 31, 2025, an increase from RMB 1,709,744,921.17 at the end of 2024[16]. - Total liabilities were RMB 1,977,261,780.79 as of March 31, 2025, slightly down from RMB 1,977,971,310.67 at the end of 2024[17]. - Shareholders' equity totaled RMB 2,874,006,975.66 as of March 31, 2025, compared to RMB 2,870,706,392.77 at the end of 2024[17]. Cash Flow - The net cash flow from operating activities was negative at -¥108,861,607.63, an improvement from -¥135,326,803.12 in the same period last year[4]. - The company reported a cash flow from operating activities net amount of CNY -108,861,607.63 for Q1 2025, an improvement from CNY -135,326,803.12 in Q1 2024[24]. - The company’s investment activities generated a net cash flow of CNY -77,092,006.71 in Q1 2025, an improvement from CNY -136,666,844.65 in Q1 2024[24]. - The cash and cash equivalents at the end of Q1 2025 were CNY 823,797,571.09, down from CNY 935,563,412.14 at the end of Q1 2024[25]. Strategic Focus - The company is focusing on enhancing profitability by prioritizing profit over scale, leading to a reduction in low-margin businesses[8]. - The company plans to focus on market expansion and new product development in the upcoming quarters[13]. Shareholder Information - The total number of shareholders and their respective holdings were disclosed, with the top shareholder holding 9.88% of the shares[9][11]. Return on Equity - The weighted average return on equity improved to 0.18%, up by 0.10 percentage points compared to the previous year[4]. Non-Recurring Items - Non-recurring gains and losses amounted to ¥2,849,890.74, primarily due to government subsidies and other factors[6][7].

Financial Data and Indicators - The basic earnings per share for Q1 2025 is 0.0300 yuan, representing a 50% increase compared to Q1 2024's 0.0200 yuan [1] - The net profit for Q1 2025 is 0.05 billion yuan, a significant increase of 150% from Q1 2024's 0.02 billion yuan [1] - The return on equity for Q1 2025 is 0.18%, which is a 125% increase from Q1 2024's 0.08% [1] - The total operating revenue for Q1 2025 is 6.04 billion yuan, showing a decrease of 9.04% compared to Q1 2024's 6.64 billion yuan [1] - The net asset per share has decreased by 28.28% to 16.99 yuan in Q1 2025 from 23.69 yuan in Q1 2024 [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 65.9179 million shares, accounting for 40.1% of the circulating shares, with no change from the previous period [2] - The largest shareholder, Xie Yingbo, holds 16.2394 million shares, representing 9.88% of the total share capital, with no change [2] - Other significant shareholders include Zhang Qing, Zhang Hua, and Wang Jingyu, each holding approximately 4.58% to 4.59% of the total shares, with no changes in their holdings [2] Dividend Distribution - The company has announced that there will be no distribution or transfer of dividends this time [3]

Group 1: Urgency in Major Projects - The construction of major projects in Fengxian New Town is driven by a sense of urgency, focusing on timely investment and commencement to address both corporate investment efficiency and local community needs [1][2] - The renovation of Dingfeng Soy Sauce Factory, which began in January 2022, is set to open in May 2023, enhancing public amenities and providing 295 parking spaces [2] - The new Xinhua Hospital branch in Fengxian, with a bed count of 4.77 per thousand people, is expected to alleviate local healthcare challenges, with trial operations starting on June 28 [2] Group 2: Long-term Industry Development - The "Oriental Beauty Valley" initiative, proposed in 2015, has seen significant growth, with the Titan Technology Life Science Headquarters being a new focal point for the health industry [3] - The life sciences sector requires a long-term commitment, with support for research teams through funding and resources to shorten project development cycles [3] - The area has attracted leading companies in cosmetics and biomedicine, with a brand value exceeding 33.8 billion and an industry scale nearing 100 billion [3] Group 3: Strategic Planning and Development - The Digital Jiang Hai Phase I Park is a key project in Fengxian New Town, emphasizing careful planning due to the higher costs associated with "industrial building" projects [4] - The park's design requires meticulous consideration of infrastructure such as lifting points and ventilation systems, reflecting a deep understanding of industrial development patterns [4]

Financial Performance - The company's operating revenue for 2024 was CNY 2,883,520,638.14, representing a 4.11% increase compared to CNY 2,769,649,016.88 in 2023[22]. - The net profit attributable to shareholders for 2024 was CNY 12,892,914.72, a significant decrease of 82.23% from CNY 72,571,508.67 in 2023[22]. - The net profit after deducting non-recurring gains and losses was CNY 5,720,909.40, down 88.87% from CNY 51,386,347.86 in the previous year[22]. - The company's cash flow from operating activities turned positive, reaching CNY 189,009,610.70, a substantial improvement from a negative cash flow of CNY -124,528,370.14 in 2023[23]. - The total assets increased by 10.49% to CNY 4,848,677,703.44 in 2024, compared to CNY 4,388,324,960.93 in 2023[23]. - Basic earnings per share decreased by 87.10% to CNY 0.08 in 2024, down from CNY 0.62 in 2023[24]. - The company's operating costs increased by 5.43% to 2,302,369.88 million RMB, slightly outpacing revenue growth, leading to a decrease in gross margin[128]. - Financial expenses surged by 64.38% to 35,192.77 million RMB due to increased short-term and long-term borrowings[128]. - The company reported a significant increase in goodwill by 51.50% to CNY 152,619,463.82 due to the acquisition of three new companies[150]. Research and Development - The R&D expenditure as a percentage of operating revenue was 5.47% in 2024, slightly down from 5.68% in 2023[24]. - Research and development expenses rose by 4.63% to 147,623.26 million RMB, reflecting the company's commitment to enhancing new product development capabilities[128]. - The company applied for 61 new patents and software copyrights during the reporting period, obtaining 34, bringing the total to 310, including 73 invention patents[61]. - The company has not formed new core technologies during the reporting period but has increased investment in product-related technologies, focusing on synthetic reagents, biological reagents, high-purity solvents, and small instruments[59]. - The company is committed to investing in new product development and technology to drive future growth[186]. Market Strategy and Expansion - The company is focusing on expanding its market share in key product lines and enhancing collaboration with major clients[34]. - The company aims to enhance its competitive advantage by continuously developing high-quality, unique products through increased R&D investment[55]. - The company intends to actively expand overseas channels to establish a foundation for its proprietary brand products in international markets[174]. - The company is considering strategic acquisitions to bolster its market position, with a focus on companies that complement its existing product offerings[187]. - The company plans to pursue mergers and acquisitions during the industry's consolidation phase to enrich its proprietary brand product line and enhance competitiveness[171]. Corporate Governance - The company has received a standard unqualified audit report from Da Xin Accounting Firm[5]. - The company has confirmed that all board members attended the board meeting[5]. - The company has not reported any significant changes in its registered address or office location[15]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not experienced any violations of decision-making procedures regarding external guarantees[8]. - The company has established specialized committees, including an audit committee and a strategic committee, to enhance governance[199]. Risk Management - The company has outlined potential risks in its annual report, which investors should be aware of[7]. - The company faces risks related to procurement delays and the need for diverse product offerings to maintain user experience and reputation[120]. - The company is at risk of core technology leakage due to reliance on OEM manufacturers for production, which could impact its competitive advantage[119]. - The company has improved its operational efficiency, reducing the delivery cost per order by approximately 7.32%[36]. Product Development and Innovation - The company has developed a flow chemistry technology that enhances reaction efficiency and safety, allowing for continuous production with a small footprint of 5 square meters[56]. - The project aims to optimize reaction processes in microchannel technology, addressing issues related to fluid transport, heat transfer, and mass transfer for large-scale production[69]. - The project has established a high-throughput screening platform for drug discovery and development, focusing on antiviral and anticancer new drugs[70]. - The company is focusing on the development of environmentally friendly and safe synthesis methods for its products[79]. - The project has developed over 10 types of fluorinated key drug building blocks with a purity exceeding 98%[83]. Financial Management - The company plans to implement a capital increase through retained earnings, with a projected profit distribution of 70.76% for the financial director[185]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 572.55 million RMB[193]. - The company has restricted assets totaling 509,914,964.16 RMB, which includes cash of 3,878,692.96 RMB, intangible assets of 15,402,237.50 RMB, fixed assets of 154,677,054.70 RMB, and construction in progress of 335,956,979.00 RMB[153]. - The company plans to use part of the idle raised funds for cash management and has proposed to extend some fundraising projects[198]. Shareholder Engagement - The company held a total of 3 shareholder meetings in 2024, ensuring compliance with regulations and allowing all shareholders to exercise their voting rights[178]. - The board of directors convened 6 meetings in 2024, reviewing and approving the annual report and other matters[179]. - The independent director Jiang Wengong resigned due to personal work commitments during the reporting period[194]. - The independent director Luo Shoujian was elected as a replacement independent director[194].

二、董事会对独立董事独立性情况的评估意见 经深入核查,独立董事胡颖女士、骆守俭先生、朱正刚先生的任职经历以 及相关自查文件,确认上述人员未在公司担任除独立董事以外的任何职务,也 未在公司主要股东公司担任任何职务,与公司以及公司主要股东之间不存在利 害关系或其他可能妨碍其进行独立客观判断的关系。 公司独立董事在 2024 年度始终保持高度的独立性,其履职行为符合《上市 公司独立董事管理办法》《上海证券交易所科创板股票上市规则》《上海证券交 易所科创板上市公司自律监管指引第 1 号 -- 规范运作》等法律法规要求及 《公司章程》等规章制度中关于独立董事独立性的严格规定和要求,有效履行 了独立董事职责,为董事会决策提供了公正、独立的专业意见,有效发挥了参与 决策、监督制衡、专业咨询作用。 上海泰坦科 2025 年 上海泰坦科技股份有限公司 董事会对独立董事独立性自查情况的专项报告 一、独立董事独立性自查情况 上海泰坦科技股份有限公司(以下简称"公司")现有独立董事3人,分别 为胡颖女士、骆守俭先生、朱正刚先生。根据《上市公司独立董事管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-016 上海泰坦科技股份有限公司 关于 2024 年度计提减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、计提减值准备情况概述 为客观、公允地反映上海泰坦科技股份有限公司（以下简称"公司"）截至 2024 年 12 月 31 日的财务状况及 2024 年度的经营成果，本着谨慎性原则，根据 《企业会计准则》及公司会计政策、会计估计的相关规定，公司对截至 2024 年 12 月 31 日公司及子公司的应收票据、应收账款、其他应收款、存货、合同资产 等进行了减值测试，并根据减值测试的结果相应计提了减值准备。 2024 年度，公司计提资产减值损失和信用减值损失共计人民币 2,294.37 万 元，具体情况如下： 合同资产的减值准备计提参照预期信用损失的确定方法。在每个资产负债表 日评估相关金融工具的信用风险自初始确认后是否显著增加。经测试，公司 2024 年度计提合同资产减值损失 0.02 万元。 （二）信用减值损失 本公司以预期信用损失为基础，对 ...

对 2024年度会计师事务所履职情况评估报告 上海泰坦科技股份有限公司(以下简称"公司")聘请大信会计师事务所(特 殊普通合伙)( 以下简称"大信"或者"大信所")作为对公司 2024 年度财务报 告出具审计报告的会计师事务所。 上海泰坦科技股份有限公司 根据财政部、国务院国有资产监督管理委员会、中国证券监督管理委员会颁 布的《国有企业、上市公司选聘会计师事务所管理办法》,公司对大信会计师事 务所在近一年审计中的履职情况进行了评估。经评估,公司认为,近一年大信会 计师事务所资质等方面合规有效,履职能够保持独立性,勤勉尽责、公允表达意 见。具体情况如下: 一、会计师事务所的基本情况 (一) 资质条件 1、基本信息 大信会计师事务所(特殊普通合伙)(以下简称"大信")成立于 1985年, 2012年 3 月转制为特殊普通合伙制事务所,总部位于北京,注册地址为北京市 海淀区知春路 1 号 22 层 2206。大信在全国设有 32 家分支机构,在香港设立了 分所,并于 2017年发起设立了大信国际会计网络,目前拥有美国、加拿大、澳 大利亚、德国、法国、英国、新加坡等 38 家网络成员所。大信是我国最早从事 证券服务业 ...

公司代码：688133 公司简称：泰坦科技 上海泰坦科技股份有限公司 2024年度内部控制评价报告 上海泰坦科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 2. 财务报告内部控制评价结论 √有效 □无效 根据公司财务报告内部控制重大缺陷的认定情况，于内部控制评价报告基准日，不存在财务报告内 部控制重大缺陷，董事会认为，公司已按照企业内部控制规范体系和相关规定的要求在所有重大方面保 持了有效的财务报告内部控制。 3. 是否发现非财务报告内部控制重大缺陷 □是 √否 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何 ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-014 上海泰坦科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟续聘的会计师事务所名称：大信会计师事务所（特殊普通合伙） 上海泰坦科技股份有限公司（以下简称"公司"）第四届董事会第十四次会 议审议通过了《关于续聘会计师事务所的议案》，同意公司续聘大信会计师事务 所（特殊普通合伙）（以下简称"大信会计"）为公司 2025 年度审计机构，本议 案尚需提交公司股东大会审议。现将相关事项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 大信会计师事务所（特殊普通合伙）（以下简称"大信"）成立于 1985 年， 2012 年 3 月转制为特殊普通合伙制事务所，总部位于北京，注册地址为北京市 海淀区知春路 1 号 22 层 2206。大信在全国设有 32 家分支机构，在香港设立了 分所，并于 2017 年发起设立了大信国际会计网络，目前拥有美国、加拿大、澳 大利亚、德国、法国、英国、 ...